Sign in
Enrolling by invitationNo phase

Effects of Total Thyroid Removal on Parathyroid Function and Quality of Life

Key facts

Who runs it
Aarhus University Hospital
Where
Denmark1 site in 1 countryChoose a country to see its sites
Trial code
Status
Enrolling by invitation
People taking part
150 people, planned
Started
1 Jan 2026
Expected to end
Dec 2028
Type of study
Interventional, 4 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • high-dose calcium (400 mg x 4), vitamin D (19 mikg x 4), and active vitamin D supplementation (2 mikg x 2)
  • Ommit routine blood test post operative day 1
Record updated
2 February 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (5)Hide the full registry criteria

Who can take part

  • Adult patients (≥18 years) undergoing Total thyroidectomy with intraoperative PTH measurements

Who cannot take part

  • Malabsorption (intestinal resection or gastric by-pass)
  • Previous thyroid or parathyroid operations
  • Renal insufficiency (eGFR<30 ml/min) or deemed clinically high-risk requiring mandatory biochemical monitoring
  • Hypercalcemia (Ca2+ > 1.32 mmol/L)

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Hypoparathyroidism post-surgical or quality of life

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Postoperative hypoparathyroidism (hypoPT) is the most frequent complication after total thyroidectomy (TT). It is caused by impaired parathyroid function, leading to low calcium levels, patient discomfort, reduced quality of life (QoL), and increased healthcare costs. Traditionally, all TT patients undergo routine postoperative blood testing and standard calcium supplementation, despite varying individual risk.

Read full original descriptionShow less

This investigator-initiated project aims to improve patient outcomes by using intraoperative parathyroid hormone (ioPTH) measurements to guide postoperative care. The ioPTH decline reflect parathyroid function immediately after surgery and can identify patients at high or low risk of hypoPT.

The study is designed as a prospective, randomized controlled trial (RCT) with two arms:

Arm A (<75% ioPTH decrease): Patients randomized to either omission of routine postoperative calcium/PTH blood tests or standard monitoring.

Arm B (>75% ioPTH decrease): Patients randomized to either early high-dose calcium and vitamin D supplementation or standard therapy.

Primary outcomes are calcium and PTH levels postoperatively, incidence of hypocalcemia, and healthcare resource use. Secondary outcomes include QoL assessed by validated questionnaires (ThyPro39, SF-36, HPQ27), transient and permanent hypoPT rates, and other surgical complications.

By tailoring care to individual risk, the study aims to safely reduce unnecessary blood tests and optimize early treatment for high-risk patients. This approach has the potential to shorten hospital stays, reduce symptoms, improve QoL, and lower costs. The findings may influence clinical guidelines nationally and internationally, supporting more personalized and evidence-based management of TT patients.

The 4 groups in the trial

  • <75 % fall in intraoperative parathyroidhormoneNo study treatment, for comparison

    Standard blood test on post operative day 1 including PTH and P-ca

  • <75 % fall in intraoperative parathyroidhormone experimentalTreatment being tested

    Ommit routine blood test on post operative day 1

    Treatment: Ommit routine blood test post operative day 1

  • >75% fall in intraoperative parathyroidhormoneNo study treatment, for comparison

    Standard treatment

  • >75% fall in intraoperative parathyroidhormone experimentalTreatment being tested

    Start in Unikalk 4 times per day + d-vitamin + alfacalcidol 2 microgram 2 times per day.

    Treatment: high-dose calcium (400 mg x 4), vitamin D (19 mikg x 4), and active vitamin D supplementation (2 mikg x 2)

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Impact of Total Thyroidectomy on Parathyroid Function and Quality of Life
Criteria questions
Built from NCT07381998, who can take part
Record updated
2 February 2026